drugset
drugset / Trial / NCT05355077

Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

NCT05355077 ↗

Phase 1 Withdrawn Shanghai Vinnerna Biosciences Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1, open-label, dose-escalation, multiple-dose study to investigate pharmacokinetics and safety of JT001 (VV116) in Caucasian healthy subjects.

Timeline

Start
2022-05-02
Primary completion
2022-08-01
Completion
2022-10-24

Drugs

EvaluationDrugModalityDoseRoute
Subject JT001 Small molecule 200 mg Oral
Subject JT001 Small molecule 400 mg Oral
Subject JT001 Small molecule 600 mg Oral

Indications

No indication recorded.